Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 12Active not recruiting 4Not yet recruiting 3Suspended 2Withdrawn 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Carcinoma, Merkel Cell 1

Interventions

Specimen Handling 40Magnetic Resonance Spectroscopy 28Carboplatin 19Gemcitabine 18Biopsy 17Cyclophosphamide 15fludarabine 14Paclitaxel 14Cisplatin 14pembrolizumab 13Oxaliplatin 12Dexamethasone 12Radiotherapy 11Injections 11Nivolumab 10Interviews as Topic 9venetoclax 8Irinotecan 8Fluorouracil 8Bevacizumab 8X-Rays 7Radiosurgery 7Drug Therapy 7Capecitabine 7Bortezomib 7cemiplimab 6Rituximab 6Pemetrexed 6Doxorubicin 6Calcium Dobesilate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × decitabine and cedazuridine drug combination × 30 days × Clear all
NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

University of Wisconsin, Madison

Phase 1/2 Not yet recruiting
31 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT07153497 2026-05-13

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
132 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07437950 2026-05-13

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
126 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡